From Wikipedia, the free encyclopedia
|Chemical and physical data|
|Molar mass||143.6 kg/mol|
Guselkumab is a monoclonal antibody. By targeting the IL-23 subunit alpha (p19 subunit) (which is not part of IL-12) guselkumab was designed to block interleukin-23 but not IL-12. Guselkumab was developed by Janssen Global Services, LLC.
- Ustekinumab, a monoclonal antibody targeting both IL-12 and IL-23 and used to treat plaque psoriasis, launched in the United States under the brand name Stelara
- Tildrakizumab, another experimental, IL-23-specific monoclonal antibody
- Statement On A Nonproprietary Name Adopted By The USAN Council - Guselkumab, American Medical Association.
- Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA (Jan 2001). "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12". Immunity. 13 (5): 715–25. PMID 11114383. doi:10.1016/S1074-7613(00)00070-4.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|